Homegrown pharma major Glenmark Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic Lacosamide tablet, indicated for prevention and control of seizures.
The approval granted by the US Food & Drug Administration (USFDA) to the company's arm Glenmark Pharmaceuticals Inc, USA, is for Lacosamide tablets of strengths 50 mg, 100 mg, 150 mg and 200 mg, Glenmark said in a statement.
These are generic versions of Vimpat tablets of the corresponding strengths of UCB, Inc.
"The company plans to launch the product immediately," it added.
Glenmark Pharmaceuticals Ltd Chief Commercial officer Robert Crockart said, "the FDA approval for generic Lacosamide Tablets USP reiterates our ongoing commitment to make treatment options more accessible for patients. We look forward to quickly launching this product in the US market."
Citing IQVIA sales data for the 12 months ending January 2022, the company said Vimpat Tablets, 50 mg, 100 mg, 150 mg and 200 mg market achieved annual sales of approximately USD 1.7 billion.
Glenmark said its current portfolio consists of 174 products authorised for distribution in the US marketplace and 45 ANDAs (Abbreviated New Drug Applications) pending approval with the USFDA.
Glenmark Pharma To Sell 75% Stake In Life Sciences To Nirma For $680 Million Glenmark Arm Files Papers For Rs 1,160 Crore Glenmark Life Sciences' IPO Glenmark Defends Price Of Its COVID-19 Drug Favipiravir Version World's Largest Isolated Tribe Makes Rare Appearance In New Footage 4 Passengers Die As 12 Coaches Of Chandigarh-Dibrugarh Express Derail In UP Why BJP Lost Lok Sabha Polls In Uttar Pradesh - 6 Reasons In Party Report Woman Dies After Jumping Off Elevated Platform At Delhi Metro Station: Cops No Coercive Action Against Delhi-NCR Home Buyers Over EMI: Supreme Court 60 Rare Siamese Crocodiles Hatch In Cambodia In A Conservation Win Track Latest News Live on NDTV.com and get news updates from India and around the world.